Article Text

Download PDFPDF
Clinical round-up
  1. Sophie Herbert1,
  2. Lewis Haddow2
  1. 1Department of GUM/HIV, Derby Hospitals NHS Foundation Trust, Derby, UK
  2. 2Research Department of Infection and Population Health, Centre for Sexual Health & HIV Research, University College London, London, UK
  1. Correspondence to Dr Sophie Herbert, Department of GUM/HIV, Derby Hospitals NHS Foundation Trust, Derby, DE1 2QY UK; sophieherbert{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

HPV vaccination

As we write, the Food and Drug Administration (USA) has approved the use of the 9-valent human papilloma virus (HPV) vaccine. Questions remain, however, about who to vaccinate. Should we be vaccinating boys/men, and how old is too old to be vaccinated? Skinner et al1 go some way to answering the second question with their interim analysis. The VIVIANE study is a multicentre double-blinded randomised controlled trial looking at the efficacy of the bivalent HPV 16/18 vaccine in women >25 years. (The PATRICIA study previously looked at this vaccine in women <25 years).2 In total, 15% of women included in the trial had prior exposure to HPV, and primary endpoints were persistent HPV 16/18 infection at 6 months or CIN1 or greater associated with these subtypes. Vaccine efficacy was 81.1% for the total group and 86.4% for those who were seropositive for HPV but negative for HPV DNA at baseline, after 40.3-month follow-up. The vaccine appears to be more efficacious in the group aged 26–35 years than in …

View Full Text


  • Contributors SH and LH decided on the content and wrote the manuscript.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.